Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
Alterity Therapeutics CEO to participate in ShareCafe Hidden Gems webinar on February 1 and 2, 2024, for Australian and US participants, offering an archived replay. The event aims to provide further details on the company's disease modifying treatments for neurodegenerative diseases.
01/29/2024 - 07:24 AM
MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times:
AUSTRALIA PARTICIPANTS:
UNITED STATES PARTICIPANTS:
To access further details of the event and to register at no cost, please click here , or copy and paste the following link into your internet browser:https://us02web.zoom.us/webinar/register/WN_Xb_tWO_eR6yXkSyaMmqhrA#/registration
An archived replay will be made available following the event.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
Investor and Media Contacts:
Australia we-aualteritytherapeutics@we-worldwide.com
U.S. remy.bernarda@iradvisory.com
The ShareCafe Hidden Gems webinar will take place on February 2, 2024, at 12:30 p.m. AEDT for Australian participants.
The ShareCafe Hidden Gems webinar will take place on February 1, 2024, at 5:30 p.m. PT / 8:30 p.m. ET for US participants.
To access further details of the event and to register at no cost, please click here, or copy and paste the following link into your internet browser: https://us02web.zoom.us/webinar/register/WN_Xb_tWO_eR6yXkSyaMmqhrA#/registration
Yes, an archived replay will be made available following the event.
Alterity Therapeutics Ltd
ATHE Rankings
#4167 Ranked by Stock Gains
ATHE Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Biotechnology, Health Technology
Country
Australia
City
Melbourne
About ATHE
alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.
